Er ofte en del motstand i områdene aksjen er i nå (ma-200 som er på 382 kr), men blåste greit forbi, så får man se om aksjen holder seg. Og som du sier 390 ser ut til å være er område med selgere. Reagert ned 3 ganger
1 Like
Den arbejder på det jeg tror det lykkes.
Pusher 400 i USA nå.
4 Likes
Avslutter dagen nesten på dagens high i USA, fin avslutning på uken. Nå får folk bare bygge litt fomo i helgen når de ser en trend som virkelig ser ut til å ha snudd.
Ta ut 200 dagers snitt på den måten ADR gjorde i dag på en fredag er et av de største kjøpssignalene jeg har i min blokk.
Dansk ikke fullt så bastant, men håper på litt fomo i helgen jeg og
4 Likes
Hva tenker dere om Novo gitt situasjonen med Danmark og Grønland? Er det en risiko at Trump vil stikke kjepper i hjulene?
Med Trump - er der intet der er sikkert
Dog tvivler jeg, med tanke på at NOVO har flere fabrikker og mange ansatte i USA,
Markedet tror i alle fall det gitt at den stengte på 400 i US på fredag.
Ser fristende ut for en arbitrasjetrade.
Takk for hjelpen ditt oransje troll
4 Likes
Haha. Men streken din er faktisk rett, close over den øverste oransje pixelen, så har man et solid brudd oppover.
2 Likes
Amerikanerne fnyser av danskenes nedsabling av kursen (ca 388 overnight nå)
Er du sikker på at de kursene er representative, markedet var jo stengt for MLK day i går??
Handles “overnight” fra ca kl 20 i amerikansk tid i går
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
2026-01-20 14:30:00
Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect Biosystems
Aspect will lead development, manufacturing and commercialisation, and Novo Nordisk will have defined rights to expand its role at a later stage
Aspect will integrate select manufacturing and R&D capabilities and expertise from the US and Denmark into its Canada-anchored platform
Bagsværd, Denmark and Vancouver, BC, Canada, 20 January 2026 – Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.
Since 2023, Aspect and Novo Nordisk have collaborated to develop cellular medicines designed to replace, repair or supplement biological functions to deliver truly disease-modifying therapies. This new phase of the partnership builds on the momentum achieved in the existing collaboration. It reflects a shared mission to accelerate the development of potentially curative medicines for serious diseases.
Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk and will lead development, manufacturing and commercialisation. Novo Nordisk will have defined rights to expand its role in later-stage development and commercialisation.
Novo Nordisk will make an additional equity investment in Aspect and provide research funding to advance these potentially curative therapies. Novo Nordisk will be eligible to receive royalties and milestone payments on future product sales from Aspect.
“Novo Nordisk was founded on a commitment to improve the lives of people living with diabetes. That commitment is as strong now as it was 100 years ago, and we have a continued focus on bringing innovation to people living with type 1 diabetes through internal and external innovation efforts,” said Jacob Sten Petersen, senior vice president, Global Research, Novo Nordisk. “Aspect brings tremendous expertise and capabilities in cellular medicines, and we are proud of our partnership with them to progress transformative cell therapies toward clinical development and potentially generating a functional cure for people living with diabetes.”
The agreement between the two companies involves integrating select Novo Nordisk cell therapy research, development, and manufacturing capabilities and expertise from the United States and Denmark into Aspect’s Canada-anchored platform. This integration will strengthen Aspect’s end-to-end capabilities and expand access to highly skilled talent.
“Our partnership with Novo Nordisk combines more than a century of their global leadership in the fight against diabetes with Aspect’s leadership in cell therapy and our biotech speed and agility, creating a powerful force multiplier to deliver clinical impact,” said Tamer Mohamed, founder and CEO, Aspect Biosystems. "By integrating key technologies and capabilities, we are strengthening our full-stack platform, accelerating our path to curative cell therapies, and advancing our vision to build a generational biotechnology company that delivers global impact for people living with serious diseases.”
Aspect’s platform is being applied to develop a new class of cellular medicines and functional cures for serious metabolic and endocrine diseases, including an islet replacement therapy for type 1 diabetes designed to restore blood glucose control without the need for chronic immune suppression. These cellular medicines are designed to be allogeneic, enabling scalable manufacturing using off-the-shelf cells.
2 Likes
395 nå.
TACO?
1 Like
Høynet kursmål i dag fra Goldman Sachs er kanskje katalysatoren som vil dra oss over 390 (og etablere seg der?) når USA åpner for handel i dag?
Så er jo igjen spørsmålet om tradere vil ta den videre ut i neste uke før man begynner å se mot tall som skal presenteres i starten av februar
1 Like
Verdt å huske at 2026 guidinga kommer da også…
Kan hende det blir en aldri så liten kalddusj.
1 Like